BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27493239)

  • 1. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
    J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 3. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.
    Marzi A; Halfmann P; Hill-Batorski L; Feldmann F; Shupert WL; Neumann G; Feldmann H; Kawaoka Y
    Science; 2015 Apr; 348(6233):439-42. PubMed ID: 25814063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
    Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice.
    Zhao W; Zhang P; Bai S; Lv M; Wang J; Chen W; Yu Q; Wu J
    Arch Virol; 2021 Dec; 166(12):3333-3341. PubMed ID: 34591172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
    Geisbert TW; Bailey M; Hensley L; Asiedu C; Geisbert J; Stanley D; Honko A; Johnson J; Mulangu S; Pau MG; Custers J; Vellinga J; Hendriks J; Jahrling P; Roederer M; Goudsmit J; Koup R; Sullivan NJ
    J Virol; 2011 May; 85(9):4222-33. PubMed ID: 21325402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
    Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
    J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein.
    Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR
    Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation in nonhuman primates of vaccines against Ebola virus.
    Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB
    Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.
    Stanley DA; Honko AN; Asiedu C; Trefry JC; Lau-Kilby AW; Johnson JC; Hensley L; Ammendola V; Abbate A; Grazioli F; Foulds KE; Cheng C; Wang L; Donaldson MM; Colloca S; Folgori A; Roederer M; Nabel GJ; Mascola J; Nicosia A; Cortese R; Koup RA; Sullivan NJ
    Nat Med; 2014 Oct; 20(10):1126-9. PubMed ID: 25194571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.